Showing results (211-220 of 258) with videos related to

Sort By:
Pageof 26
American Journal of Obstetrics and Gynecology|November 1, 1994
Evaluation of tumor-associated glycoprotein-72 and CA 125 serum markers in patients with gynecologic diseasesF Guadagni, C Marth, A G Zeimet, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 6, 2011
CD44 splice variant expression in normal and malignant uterine cervical epitheliumM Uhl-Steidl, V Q Huy, E Müller-Holzner, et al.
Geburtshilfe Und Frauenheilkunde|November 1, 1989
[The intraperitoneal installation of gamma interferon for the treatment of refractory ovarian carcinoma]C Marth, R Mull, G Gastl, et al.
British Journal of Cancer|June 15, 2013
Does thyroid-stimulating hormone influence the prognosis of patients with endometrial cancer? A multicentre trialV Seebacher, G Hofstetter, S Polterauer, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|July 29, 1998
Peritoneum and tissues of the female reproductive tract as physiological sources of CA-125A G Zeimet, F A Offner, E Müller-Holzner, et al.
International Journal of Cancer|May 15, 1989
Expression of 7F7-antigen, a human adhesion molecule identical to intercellular adhesion molecule-1 (ICAM-1) in human carcinomas and their stromal fibroblastsW Vogetseder, H Feichtinger, T F Schulz, et al.
Breast Cancer Research and Treatment|December 1, 1988
Steroid hormone receptors and prognosis in breast cancerG Daxenbichler, E P Forsthuber, C Marth, et al.
Archives of Gynecology and Obstetrics|January 23, 2018
The use of PIPAC (pressurized intraperitoneal aerosol chemotherapy) in gynecological oncology: a statement by the "Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR)", the Swiss and Austrian AGO, and the North-Eastern German Society of Gynaecologic OncologyA M Dueckelmann, D Fink, P Harter, et al.
British Journal of Cancer|March 29, 2000
Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trialG H Windbichler, H Hausmaninger, W Stummvoll, et al.
Gynecologic Oncology|September 1, 1996
Human peritoneal mesothelial cells are more potent than ovarian cancer cells in producing tumor marker CA-125A G Zeimet, C Marth, F A Offner, et al.
Pageof 26